1. Inicio
  2. Proyectos y Estudios
  3. ESTUDIO DE FASE II, ABIERTO, ALEATORIZADO Y MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE PEMIGATINIB MÁS PEMBROLIZUMAB EN COMPARACIÓN CON PEMIGATINIB SOLO Y CON EL TRATAMIENTO DE REFERENCIA COMO TRATAMIENTO DE PRIMERA LÍNEA PARA EL CARCINOMA U ROTELIAL METASTÁSICO O NO RESECABLE EN PARTICIPANTES NO APTOS PARA CISPLATINO, CUYOS TUMORES EXPRESAN MUTACIÓN O REORDENAMIENTO DE FGFR3 (FIGHT-205).

ESTUDIO DE FASE II, ABIERTO, ALEATORIZADO Y MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE PEMIGATINIB MÁS PEMBROLIZUMAB EN COMPARACIÓN CON PEMIGATINIB SOLO Y CON EL TRATAMIENTO DE REFERENCIA COMO TRATAMIENTO DE PRIMERA LÍNEA PARA EL CARCINOMA U ROTELIAL METASTÁSICO O NO RESECABLE EN PARTICIPANTES NO APTOS PARA CISPLATINO, CUYOS TUMORES EXPRESAN MUTACIÓN O REORDENAMIENTO DE FGFR3 (FIGHT-205).

Datos básicos

Código:
INCB 54828-205
Protocolo:
INCB 54828-205
EUDRACT:
2019-000721-50
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2020
Año de finalización:
2023
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

INCYTE CORPORATION

Resultados del Ensayo Clínico

[ 177 Lu]Lu-DOTA-TATE and [ 131 I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center.

Prado-Wohlwend, Stefan; (...); Merino-Torres, Juan Francisco

Article. 10.3389/fendo.2022.778322. 2022


[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence

Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda

Editorial Material. 10.1016/j.farma.2024.08.009. 2024

  • Open Access.

[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Andrés JLP, Solsona MDE

Article. 10.1016/j.farma.2023.10.004. 2024


[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024


[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.

Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.09.006. 2024

  • Open Access.

177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors

Jimenez-Fonseca, P.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2022


177-Lu-DOTATATE in 382 patients with somatostatin receptor-positive advanced tumors: Real-world data from the SEPTRALU registry

Casanovas M, Mitjavila; (...); Carmona-Bayonas, A.

Meeting Abstract. 2022


177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations - Data from 552 cases in the SEPTRALU registry

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2023


2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11611. 2021


A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Dec, 10.1007/s11060-023-04513-1, 2023)

Gately L; (...); Balana C

Correction. 10.1007/s11060-024-04581-x. 2024


A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

Gately, L.; (...); Balana, C.

Article. 10.1007/s11060-023-04513-1. 2023


A COMBINED ANALYSIS OF TWO RANDOMISED STUDIES EXPLORING THE IMPACT OF EXTENDED POST-RADIATION TEMOZOLOMIDE ON SURVIVAL OUTCOMES IN NEWLY DIAGNOSED GLIOBLASTOMA

Gately, Lucy; (...); Balana, Carmen

Meeting Abstract. 2023


A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022


A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Zozaya, Neboa; (...); Verde, Luis

Article. 10.1017/S0266462322000459. 2022


A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results

Ponce Aix, S.; (...); Paz-Ares, L.

Meeting Abstract. 2021


A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01).

Balana C; (...); Carrato C

Article. 10.1093/neuonc/noaa107. 2020


A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.

Camidge DR; (...); Smit E

Article. 10.1016/j.cllc.2022.03.003. 2022


A rare case of diffuse and bilateral pulmonary uptake in 18 F-FDG PET/CT scan.

Olivan-Sasot, P; (...); Bello-Arques, P

Editorial Material. 10.1016/j.remn.2020.11.007. 2021


A rare case of diffuse and bilateral pulmonary uptake in 18F-FDG PET/CT scan.

Olivan-Sasot, P; (...); Bello-Arques, P

Article. 10.1016/j.remnie.2020.11.002. 2021


Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group.

Battisti NML; (...); Wildiers H

Review. 10.1016/j.jgo.2020.07.008. 2020


Addressing the challenges of cancer care in older adults: The unique benefits of oncogeriatric evaluation and management.

Martinez-Peromingo, Javier; (...); Girones, Regina

Letter. 10.1016/j.regg.2023.03.002. 2023


Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting

Garrido Siles, Marga; (...); Angel Climent, Miguel

Review. 10.3390/cancers14163968. 2022


Alternatives of the pelvic sentinel lymph node migration pathway in early ovarian cancer: the simplest the best.

Lago, Victor; (...); Domingo, Santiago

Article. 10.1136/ijgc-2023-004912. 2023


Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.

Passaro, A; (...); Cho, B C

Article. 10.1016/j.annonc.2023.10.117. 2024


An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.

Dowlati, Afshin; (...); Carpeno, Javier de Castro

Meeting Abstract. 2022


Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital

Valero García S; (...); Poveda Andrés JL

Article. 10.1177/10781552211038518. 2021


Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.

Ruano-Ravina A; (...); Oramas J

Article. 10.21037/tlcr-21-559. 2021


Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).

Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ

Letter. 10.1111/jdv.19432. 2023


Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.

Andric, Zoran; (...); Ciardiello, Fortunato

Article. 10.1016/j.jtocrr.2022.100461. 2023


Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez R; (...); Poveda Andrés JL

Article. 10.1136/ejhpharm-2021-002741. 2021


Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors

Garcia-Sanchez, J.; (...); Lahoz, A.

Meeting Abstract. 2021


Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022


Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.

Garcia-Del-Muro, Xavier; (...); Alemany, Ramon

Article. 10.1158/1078-0432.CCR-24-2636. 2025


Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial

Vidal, O. J. Juan; (...); Wolf, J.

Meeting Abstract. 10.1016/j.annonc.2023.09.2424. 2023


Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021


Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

Franco, FF; (...); Provencio, M

Meeting Abstract. 10.1016/j.annonc.2021.08.1771. 2021


Clinical experience of whole body and tumour dosimetry of 131-I-mIBG treatment for pediatric patients

Espallardo, I. Torres; (...); Prado-Wohlwend, S.

Meeting Abstract. 2023


ComBat harmonization in different PET imaging scenarios

Gandia-Ferrero, M.; (...); Marti-Bonmati, L.

Meeting Abstract. 2023


Comparison of 3D dosimetry methods in hepatic radioembolisation with Y-90 microspheres

Carrasco Vela, N.; (...); Torres-Espallardo, I.

Meeting Abstract. 2021

  • Open Access.

Comparison of protocols with respiratory-gated (4D) motion compensation in PET/CT: open-source package for quantification of phantom image quality.

Martinez-Movilla, Andrea; (...); Carles, Montserrat

Article. 10.1186/s40658-022-00509-4. 2022


Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: Results of the RING observational trial.

Romero A; (...); Provencio M

Article. 10.1002/1878-0261.12832. 2020


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023


Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).

García-Campelo R; (...); Dómine M

Correction. 10.1007/s12094-023-03290-7. 2023


Correction: Pardo-Sánchez et al. Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. Cancers 2021, 13 , 2980.

Pardo-Sanchez, Jose Miguel; (...); Farràs R

Article. 10.3390/cancers13194825. 2021


Correction: Update on the management of elderly patients with colorectal cancer.

Soler-González G; (...); Gironés-Sarrió R

Correction. 10.1007/s12094-023-03351-x. 2024


Correlation Between Clinical Characteristics And Effective Washout Time In Patients Treated With High Radioiodine Activities

Guerrero Calatayud, C.; (...); Bello Arques, P.

Meeting Abstract. 2023


Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

Reck, M.; (...); John, T.

Correction. 10.1016/j.esmoop.2021.100345. 2021


COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024


Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021


COVID-19 and hospitalised cancer patients: Now it's time for patients to talk

Arrue, BD; (...); Sarrio, RG

Meeting Abstract. 10.1016/j.annonc.2020.08.2061. 2020


Current treatment landscape for oligometastatic non-small cell lung cancer

Garde-Noguera, Javier; (...); Counago, Felipe

Article. 10.5306/wjco.v13.i6.485. 2022


Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024


Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)

Aransay, N. Reguart; (...); Vila, A. Lloansi

Meeting Abstract. 10.1016/j.annonc.2023.09.2442. 2023


Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Suay, G.; (...); Juan-Vidal, O.

Meeting Abstract. 2024


Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Ahn, Myung-Ju; (...); Sands, Jacob

Article. 10.1200/JCO-24-01544. 2024


Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01

Sands, J.; (...); Ahn, M-J

Meeting Abstract. 2024


Delphi consensus on strategies in the management of opioid-induced constipation in cancer patients

Sarrio, RG; (...); Porta-Sales, J

Article. 10.1186/s12904-020-00693-z. 2021


Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021


Determination of essential biomarkers in lung cancer: A real-world data study in Spain

Calvo de Juan, V.; (...); Provencio Pulla, M.

Meeting Abstract. 10.1016/j.annonc.2022.02.048. 2022


Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

Provencio, Mariano; (...); Torrente, Maria

Article. 10.1186/s12885-022-09830-8. 2022


Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024


Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024


Development and validation of an early death risk score for older patients treated with chemotherapy for cancer.

Batlle, JF; (...); Molina-Garrido, MJ

Meeting Abstract. 2020


Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer

Feliu, J; (...); Molina-Garrido, MJ

Article. 10.3390/jcm10081615. 2021


Development of a predictive model for early detection of lung cancer: SREAL-eLUNG study

Vidal, O. J. Juan; (...); Martinez, B. Valdivieso

Meeting Abstract. 2023


Do SPECT CT and sentinel node tecnhique increase the diagnosis of metastasic disease in prostate cancer?

Perez Ardavin, J.; (...); Vera-Donoso, C. D.

Meeting Abstract. 2022


Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from Arm A of the phase 2 BALTIC study

Reinmuth, Niels; (...); Bondarenko, Igor

Meeting Abstract. 2022


ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN

Fernandez-Barcelo, C.; (...); Sampietro-Colom, L.

Meeting Abstract. 2023


ECONOMIC IMPACT OF THE NSCLC MOLECULAR DIAGNOSIS IN SPAIN: A RETROSPECTIVE ANALYSIS OF HEALTHCARE RESOURCES USE AND ASSOCIATED COSTS FROM THE LUNG-ONE STUDY

de Castro, J; (...); Rojo, F

Meeting Abstract. 2020


Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021


Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A multicenter study

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2023


Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).

Brandao, Mariana da Rocha Almeida; (...); Felip, Enriqueta

Meeting Abstract. 2024

  • Open Access.

Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study.

Mitjavila, Mercedes; (...); Carmona-Bayonas, Alberto

Article. 10.1007/s00259-023-06166-8. 2023


Elderly glioblastoma patients: Survival analysis according adjuvant therapy and tumor molecular analysis.

Angeles Vaz, Maria; (...); De Las Penas Bataller, Ramon

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.e14046. 2021


Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry

Franco, F; (...); Provencio, M

Article. 10.1371/journal.pone.0251761. 2021


European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient.

Suay, Guillermo, Aparisi, Francisco, Juan-Vidal, Oscar

Article. 10.21037/cco-23-100. 2024


Evaluation of 177Lu-DOTATATE treatment in patients with metastasic or unresectable paragangliomas and pheochromocytomas

Canon Sanchez, J.; (...); Utrera Costero, A.

Meeting Abstract. 2021


Experience of GEINO (Spanish cooperative group for research in neuro-oncology) oncologists in the management of adult medulloblastoma

Villar, MV; (...); Santos, JD

Meeting Abstract. 10.1016/j.annonc.2021.08.008. 2021


Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.

Arriola E; (...); Felip E

Article. 10.1007/s40261-024-01379-7. 2024


Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer.

Nadal E; (...); Gironés R

Article. 10.1007/s12094-023-03286-3. 2023


Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer.

Torregrosa-Maicas MD; (...); Gironés-Sarrió R

Article. 10.1007/s12094-021-02766-8. 2022


Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).

Gately L; (...); Balana C

Article. 10.1007/s11060-024-04668-5. 2024


FAMetA: a mass isotopologue-based tool for the comprehensive analysis of fatty acid metabolism.

Alcoriza-Balaguer MI; (...); Lahoz A

Article. 10.1093/bib/bbad064. 2023


Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

Calvo, V.; (...); Provencio, M.

Meeting Abstract. 2021


Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021


Final database lock results of the phase 2 cohort of lenvatinib plus pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma

Lee, Chung-Han; (...); Motzer, Robert J.

Meeting Abstract. 2023


First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS)

Carbone, David Paul; (...); Reck, Martin

Meeting Abstract. 2023


First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).

Carbone, David Paul; (...); Reck, Martin

Meeting Abstract. 10.1200/JCO.2023.41.17_suppl.LBA9023. 2023


First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)

Andric, Z. G.; (...); Ciardiello, F.

Meeting Abstract. 2021


First-line Nivolumab (N) plus Ipilimumab (I) plus Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update

Baclin, Firas; (...); Reck, Martin

Meeting Abstract. 2024


First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

Reck, Martin; (...); John, Tom

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9000. 2021


First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

Paz-Ares, L.; (...); Carbone, D. P.

Meeting Abstract. 2021


First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): 2-year update from CheckMate 9LA

Reinmuth, N.; (...); John, T.

Meeting Abstract. 2021


First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

Paz-Ares, Luis; (...); Reck, Martin

Article. 10.1016/S1470-2045(20)30641-0. 2021


First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.

Ready, Neal E.; (...); Paz-Ares, Luis

Article. 10.1136/jitc-2022-006127. 2023


First-line Nivolumab plus Ipilimumab plus Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

Carbone, D.; (...); Lu, S.

Meeting Abstract. 2021


First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Paz-Ares, Luis G.; (...); Carbone, David P.

Article. 10.1016/j.jtho.2022.10.014. 2023


First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

Reck M; (...); John T

Article. 10.1016/j.esmoop.2021.100273. 2021


First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

Reck, Martin; (...); Carbone, David P.

Article. 10.1016/j.ejca.2023.01.015. 2023


Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.

Reck, Martin; (...); Paz-Ares, Luis G.

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.8560. 2024


Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.

Reck M; (...); Paz-Ares LG

Article. 10.1016/j.ejca.2024.114296. 2024


Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.

Carbone DP; (...); Reck M

Article. 10.1136/jitc-2023-008189. 2024


FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)

Le, Xiuning; (...); Wang, Jie

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS8666. 2024

  • Open Access.

FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations

Le, X.; (...); Wang, J.

Meeting Abstract. 2024


GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC)-A randomized, double-blind trial.

Ghiringhelli, Francois; (...); Basse, Linda

Meeting Abstract. 2022


Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024


Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study

Lopez Castro, R.; (...); Ponce Aix, S.

Meeting Abstract. 2023


Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial

Vaz, M. A.; (...); Girones, R.

Meeting Abstract. 10.1016/j.annonc.2023.09.1695. 2023


Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022


Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022


Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12

Felip, E.; (...); Duruisseaux, M.

Meeting Abstract. https://doi.org/10.1016/j.jtho.2024.09.056. 2024


High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022


High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.

Muñoz-Unceta N; (...); Grupo de trombosis y cáncer SEOM

Article. 10.1016/j.ejca.2020.10.002. 2020


Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022


Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021


How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022


Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations

Suay, Guillermo; (...); Lahoz, Agustin

Review. 10.1016/j.canlet.2024.217317. 2024


Immunogenicity of COVID-19 vaccines in lung cancer patients.

Provencio M; (...); Calvo V

Article. 10.1016/j.lungcan.2023.107323. 2023


Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: a multicenter prospective study.

Rondan, Maria Arnal; (...); Sarrio, Regina Girones

Article. 10.1007/s12094-024-03657-4. 2024


Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/cancers15061705. 2023


Impact of surgery versus other treatment options in recurrent glioblastoma. Analysis of the Spanish Group of Neurooncology Research (GEINO) RETSINE database.

Vaz Salgado, Maria Angeles; (...); De Las Penas Bataller, Ramon

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.e14047. 2021


Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation

Pardo-Sanchez, JM; (...); Farras, R

Article. 10.3390/cancers13122980. 2021


Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1097/FPC.0000000000000431. 2021


Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024


Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024


KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Mok, Tony S. K.; (...); Barlesi, Fabrice

Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8509. 2024


Leave no one behind: A global survey of the current state of geriatric oncology practice by SIOG national representatives.

Mizutani, Tomonori; (...); Kanesvaran, Ravindran

Article. 10.1016/j.jgo.2024.101709. 2024


Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.

Lee, Chung-Han; (...); Motzer, Robert J

Letter. 10.1016/j.eururo.2024.05.003. 2024


Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Lee, CH; (...); Motzer, JR

Article. 10.1016/S1470-2045(21)00241-2. 2021


Less is more: Usefulness of the sentinel node technique in radical prostatectomy

Perez Ardavin, J.; (...); Vera-Donoso, C. D.

Meeting Abstract. 2022


Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity

Spigel, DR; (...); Bunn, P

Meeting Abstract. 2021


Lu-177-DOTATATE therapy in advanced pancreatic neuroendocrine tumors: data from 187 patients of the national registry SEPTRALU

Mitjavila-Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2022


Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).

Calvo, V; (...); Provencio, M

Meeting Abstract. 2021


Lung cancer symptoms at diagnosis: results of a nationwide registry study.

Ruano-Raviña A; (...); Cerezo S

Article. 10.1136/esmoopen-2020-001021. 2020


LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

Garrido, P; (...); Felip, E

Article. 10.1002/cam4.4135. 2021


Lutetium177 in patients with stage IV neuroendocrine tumours of any origin. Data from 321 patients of the multicenter national registry

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2021


Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

  • Open Access.

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022


Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021


Medical imaging clinical trials unit: A professional need.

Penades-Blasco, Ana; (...); Marti-Bonmati, Luis

Article. 10.1016/j.ejrad.2021.110099. 2022


Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022


Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021


Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021


Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021


nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).

Morgensztern D; (...); Ong TJ

Article. 10.3389/fonc.2020.569715. 2021


National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021


National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022


New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024


NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases

Nadal, E.; (...); Bruna, J.

Meeting Abstract. 2022


Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

Reck, M; (...); Paz-Ares, LG

Meeting Abstract. 2021


Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.

Reinmuth, Niels; (...); Bondarenko, Igor

Article. 10.1158/1078-0432.CCR-24-0013. 2024


Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022


ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023


Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023


OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024


Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.

Provencio M; (...); Calvo V

Article. 10.1186/s12885-021-07922-5. 2021


OsimertinibTreatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX

Terrasa, J; (...); Provencio, M

Meeting Abstract. 2021


P25.03.B RWD OF IDH MUTANT GLIOMAS IN SPAIN, A RETSINE - GEINO STUDY

Mazariegos, M.; (...); Pineda, E.

Meeting Abstract. 10.1093/neuonc/noae144.446. 2024

  • Open Access.

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

  • Open Access.

Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group.

Aparicio, J.; (...); Germa, J. R.

Article. 10.1007/s12094-020-02393-9. 2021


PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.

Remon J; (...); Besse B

Article. 10.1016/j.cllc.2021.07.008. 2021


Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I

Ponce Aix, S.; (...); Paz-Ares, L.

Meeting Abstract. 10.1016/j.annonc.2021.10.179. 2021


Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

del Olmo-Garcia, Maria I.; (...); Merino-Torres, Juan F.

Article. 10.3390/cancers14030584. 2022


Peptide receptor radionuclide therapy with [(177)Lu]Lu-DOTA-TATE.

Prado-Wohlwend S; (...); Endocrinology Working Group of the SEMNIM

Article. 10.1016/j.remnie.2021.11.001. 2022


Peptide receptor radionuclide therapy with [Lu-177]Lu-DOTA-TATE

Prado-Wohlwend, S.; (...); SEMNIM

Article. 2022


Pericardial synovial tumor, a rare entity to diagnose by imaging.

Utrera-Costero A; (...); Bernal-Vergara JC

Editorial Material. 10.1016/j.remn.2020.10.005. 2021


Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025


Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021


Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022


Phase II trial evaluating olaparib maintenance in patients with metastatic castration resistant prostate cancer (mCRPC) after docetaxel treatment, reaching partial or stable response: SOGUG-IMANOL study.

Juan Fita, Maria Jose; (...); Heras, Lucia

Meeting Abstract. 2023


Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study.

Juan Fita, Maria Jose; (...); Angel Climent, Miguel

Article. 10.3390/cancers15215223. 2023


Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).

Nadal E; (...); Bruna J

Article. 10.1200/JCO.22.02561. 2023


Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.

Garcia del Muro, Xavier; (...); Vigues, Francesc

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.4505. 2021


Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.

Cuellar, M. Andres; (...); Garcia del Muro, Xavier

Meeting Abstract. 2020


Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).

Lee, CH; (...); Motzer, RJ

Meeting Abstract. 2020


Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses

Lee, CH; (...); Motzer, RJ

Meeting Abstract. 10.1016/j.annonc.2020.08.782. 2020


Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients

Duran, MAC; (...); Nunez, NF

Meeting Abstract. 10.1016/j.annonc.2020.08.2074. 2020


Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.

Ahn, Myung-Ju; (...); Paz-Ares, Luis

Article. 10.1080/14796694.2024.2402152. 2024


Portal vein aneurysm, an update on the subject. A case report.

Hernando Sanz A, Navarro-Aguilar V, López-Andújar R

Letter. 10.17235/reed.2020.6842/2019. 2021


Prediction of patient progression-free survival with 177Lu-DOTATATE in clinical practice: NEPTUNESEPTRALU model for patient selection

Mitjavila Casanovas, M.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2024


Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC

Felip, E.; (...); Ganti, A.

Meeting Abstract. 10.1016/j.annonc.2021.10.159. 2021


Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021


Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

  • Open Access.

Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021


Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry).

Franco, F; (...); Provencio, M

Meeting Abstract. 2021


Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) - Data from the national registry SEPTRALU

Bello, P.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2023


Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

Gutierrez, L; (...); Provencio, M

Article. 10.1186/s12885-021-08713-8. 2021


Prognostic role of geriatric assessment (GA) in patients with metastatic prostate cancer (MPCaP) attended in medical oncology.

Girones, Regina, Arnal, Maria, Forcano, Silvia

Meeting Abstract. 2023


PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors

Spigel, DR; (...); Reck, M

Meeting Abstract. 2021


Proposal of a short acquisition protocol for 18F-DOPA imaging in brain tumors:preliminary results

Orrego, N.; (...); Bello-Arques, P.

Meeting Abstract. 2024


Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

Jantus-Lewintre, E; (...); Grp Espanol Canc Pulmon GECP

Article. 10.3389/fonc.2021.695038. 2021


Radio theranostics in paragangliomas and pheochromocytomas

Wohlwend, S. Prado, Arques, P. Bello

Article. 10.1016/j.remn.2024.500017. 2024


Radio theranostics in paragangliomas and pheochromocytomas.

Wohlwend SP, Arques PB

Article. 10.1016/j.remnie.2024.500017. 2024


Radioembolization in patients with hepatocellular carcinoma: a series of 53 cases.

Olivan-Sasot, P; (...); Olivas-Arroyo, C

Article. 10.1016/j.rxeng.2021.03.001. 2023


Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.

Edelman, Martin J.; (...); DISTINCT Study Investigators

Article. 10.1016/j.lungcan.2022.03.003. 2022


Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study)

Redondo, Andres; (...); Gonzalez-Martin, Antonio

Article. 10.31083/j.ejgo4206163. 2021


Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with >= 50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study

Perea, J.; (...); Gaudens, P. Capdevila

Meeting Abstract. 2023


RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.

Paz-Ares, Luis; (...); Bunn, Paul A.

Article. 10.1002/cncr.34123. 2022


RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer

Paz-Ares, L; (...); Bunn, P

Meeting Abstract. 2021


RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting

Paz-Ares, L; (...); Bunn, P

Meeting Abstract. 2021


Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review.

Prado-Wohlwend, Stefan; (...); Merino-Torres JF

Article. 10.3389/fendo.2022.957172. 2022


RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study

Conde, E.; (...); Lopez-Rios, F.

Meeting Abstract. 2021


RET Fusion Testing in Patients With NSCLC: The RETING Study.

Conde, Esther; (...); Lopez-Rios, Fernando

Article. 10.1016/j.jtocrr.2024.100653. 2024


RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

Hernandez, S.; (...); Conde, E.

Meeting Abstract. 2022


Retreatment PRRT with 177Lu-DOTATATE in patients with progressive neuroendocrine neoplasm: Spanish clinical experience from national registry

Mitjavila Casanovas, M.; (...); Hernando, J.

Meeting Abstract. 2024


Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.

Paz-Ares, Luis G.; (...); Garassino, Marina Chiara

Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8500. 2024


Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

Paz-Ares, Luis G.; (...); Garassino, Marina Chiara

Article. 10.1200/JCO.24.00733. 2024


Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1containing Regimen: EVOKE-01

Garassino, M. C.; (...); Paz-Ares, L. G.

Meeting Abstract. 2024

  • Open Access.

Safety and efficacy of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial

Vaz, Maria Angeles; (...); Martinez-Garcia, Maria

Meeting Abstract. 2022


Same-day comparative protocol PET/CT-PET/MRI [68Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine.

Prado-Wohlwend, Stefan; (...); Merino-Torres, Juan Francisco

Article. 10.1186/s40644-023-00521-6. 2023


Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.

Spigel DR; (...); Reck M

Article. 10.1016/j.annonc.2021.01.071. 2021


Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)

Carcereny Costa, E.; (...); Provencio Pulla, M.

Meeting Abstract. 10.1016/j.annonc.2022.02.062. 2022


SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).

Garcia-Campelo, Rosario; (...); Domine, Manuel

Article. 10.1007/s12094-023-03216-3. 2023


SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).

Martínez-García M; (...); Manuel Sepúlveda-Sánchez J

Article. 10.1007/s12094-022-02803-0. 2022


SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).

Segura, Pedro Perez; (...); Losada, Estela Pineda

Article. 10.1007/s12094-023-03245-y. 2023


SEPTRALU registry of 177-Lu-DOTATATE in neuroendocrine tumors: Data from 321 patients in clinical practice

Casanovas, MM; (...); Carmona-Bayonas, A

Meeting Abstract. 2021


Sequential treatment of High-risk Neuroblastoma combining I-131 MIBG high-dose and Topotecan. First experience

Orrego, N.; (...); Bello-Arques, P.

Meeting Abstract. 2023


Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.

Provencio, Mariano; (...); Cobo, Manuel

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8531. 2021


Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.

Provencio, Mariano; (...); Cobo, Manuel

Article. 10.21037/tlcr-21-504. 2022


Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach.

Vera, Ruth; (...); del Alba, Aranzazu Gonzalez

Article. 10.1007/s12094-023-03112-w. 2023


Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis

Suay, Guillermo; (...); Juan-Vidal, Oscar

Review. 10.3390/cancers15184433. 2023


SIOG COVID-19 Working Group recommendations on COVID-19 therapeutic approaches in older adults with cancer.

Russo, Chiara; (...); Battisti NML

Article. 10.1016/j.jgo.2023.101564. 2023


SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022


SOGUG-AVELUMAB_RWD: Comprehensive analysis of real-word data to evaluate the effectiveness and safety of avelumab maintenance therapy in patients with stage IV urothelial carcinoma conducted in Spain.

Juan Fita, Maria Jose; (...); Molina Diaz, Aurea

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.e1656. 2024

  • Open Access.

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.

Del Olmo-Garcia MI; (...); Merino-Torres JF

Article. 10.3390/biomedicines9121810. 2021


Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.

Peressini M; (...); Zugazagoitia J

Article. 10.1158/1078-0432.CCR-24-0104. 2024


State of the scientific evidence and recommendations for the management of older patients with gastric cancer.

Paredero-Perez, Irene; (...); Girones-Sarrio, Regina

Article. 10.1016/j.jgo.2023.101657. 2023


Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.

Mielgo-Rubio X; (...); Couñago F

Editorial Material. 10.5306/wjco.v11.i12.983. 2020


Strategies to enhance management of HER2-positive breast cancer in the elderly: an expert consensus perspective.

Del Barco, Sonia; (...); Servitja, Sonia

Article. 10.1007/s12094-024-03838-1. 2025


Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant

Provencio-Pulla, Mariano; (...); Romero, Atocha

Meeting Abstract. 2023


Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting

Blanco, R; (...); Vidal, OJJ

Meeting Abstract. 10.1016/j.annonc.2020.08.1631. 2020


Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022


Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.

Ahn MJ; (...); Paz-Ares L

Article. 10.1056/NEJMoa2307980. 2023


Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/ijms23158526. 2022


The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022


The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022


The Role of Imaging Studies in Favor of Possible Cerebellar Multiple System Atrophy: A Case Study.

Utrera-Costero, Ana; (...); Bello-Arques, Pilar

Article. 10.1097/RLU.0000000000003767. 2021


The sentinel node with technetium-99m for prostate cancer. A safe and, mature new gold standard?

Perez-Ardavin J; (...); Vera-Donoso CD

Article. 10.23736/S1824-4785.22.03416-1. 2022


The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer.

Mislang AR; (...); Battisti NML

Letter. 10.1016/j.jgo.2021.03.003. 2021


The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.

Gomez Rueda, Ana; (...); Garrido, Pilar

Article. 10.1007/s12094-024-03404-9. 2024


The value of F-18-FDG PET/CT in two cases of Primary Pericardial Mesothelioma

Utrera-Costero, Ana; (...); Bello-Arques, Pilar

Article. 10.1007/s12350-021-02690-y. 2021


The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024


Thoracic Tumors Registry (RTT): Analysis of Clinical Features and Survival in Patients with mNSCLC in Spain.

Franco, F; (...); Provencio, M

Meeting Abstract. 2021


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer

Palanca-Ballester, Cora; (...); Sandoval, Juan

Article. 10.1186/s13148-022-01334-3. 2022


Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.

Isla D; (...); Juan-Vidal O

Article. 10.1007/s12094-020-02518-0. 2021


Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.

Lago V; (...); Domingo S

Article. 10.1016/j.ygyno.2021.03.001. 2021


Undertreatment and overtreatment in older patients treated with chemotherapy.

Feliu J; (...); Molina-Garrido MJ

Article. 10.1016/j.jgo.2020.10.010. 2020


Update on iodine-refractory differentiated thyroid carcinoma

Casas, E. Abou Jokh; (...); Casas, J. A. Vallejo

Article. 10.1016/j.remn.2023.06.005. 2023


Update on iodine-refractory differentiated thyroid carcinoma.

Jokh Casas, E A; (...); Vallejo Casas, J A

Article. 10.1016/j.remnie.2023.07.003. 2023


Update on the management of elderly patients with colorectal cancer.

Soler-Gonzalez, Gemma; (...); Girones-Sarrio, Regina

Article. 10.1007/s12094-023-03243-0. 2023


Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology.

Guillot Morales M; (...); Gironés Sarrió R

Article. 10.1007/s12094-024-03386-8. 2024


Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non-small cell lung cancer with untreated brain metastases.

Nadal, Ernest; (...); Bruna, Jordi

Meeting Abstract. 2022


Updated SIOG COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer.

Soto-Perez-de-Celis, Enrique; (...); Battisti, Nicolo Matteo Luca

Article. 10.1016/j.jgo.2022.07.005. 2022


Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report.

Simarro J; (...); Palanca S

Article. 10.3390/diagnostics12051266. 2022


VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA

Poveda, J. L.; (...); Lizan, L.

Meeting Abstract. 2023


Y-90 PET/MR imaging optimization with a Bayesian penalized likelihood reconstruction algorithm.

Calatayud-Jordan, Jose; (...); Torres-Espallardo, Irene

Article. 10.1007/s13246-024-01452-7. 2024


Campos de estudio

Compartir